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Epstein-Barr virus (EBV) strains can be distinguished by specific sequence variations in the LMP1 gene. In
this study, a heteroduplex tracking assay (HTA) specific for LMP1 was developed to precisely identify the
prototypic undeleted strain B958, other undeleted strains (Ch2, AL, NC, and Med), and strains with the
30-bp deletion (Med and Ch1). This technique also provides an estimate of the relative abundance of strains
in patient samples. In this study, EBV strains were identified in 25 hairy leukoplakia (HLP) biopsies and six
matched peripheral blood samples and throat washes with the LMP1-HTA. To investigate the relationship of
the virus found in the peripheral blood to that in the HLP lesion, the strain variants in the peripheral blood
B lymphocytes and those present within the epithelial cells in the HLP lesion and in throat washes were
identified. In many of the subjects, compartmental differences in the EBV strain profiles in the oral cavity and
peripheral blood were readily apparent. The throat wash specimens usually had a strain profile similar to that
within the corresponding HLP sample, which was distinct from the strain profile detected in the peripheral
blood. These analyses reveal that the nature of EBV infection can be very dynamic, with changes in relative
strain abundance over time as well as the appearance of new strains. The patterns of abundance in the blood
and oral cavity provide evidence for compartmentalization and for the transmission of strains between the
blood and oropharynx.
Epstein-Barr virus (EBV) is an important human pathogen
that persistently infects greater than 90% of the world’s pop-
ulation (34). Transmission occurs via infected saliva, which
results in the establishment of a persistent latent infection in
memory B lymphocytes for the lifetime of the host and a
chronic asymptomatic shedding of virions in the oral cavity
(22). Latently infected cells express a restricted pattern of viral
genes and therefore escape immune surveillance (3). However,
reactivated cells have increased viral gene expression that can
activate EBV-specific cytotoxic T lymphocytes, which limit the
proliferation of EBV-infected lymphocytes (19, 25).
As a consequence of decreased immune response, EBV-
associated diseases may appear (43). EBV may cause AIDS-
associated lymphomas and an unusual lesion of the tongue,
hairy leukoplakia (HLP) (15, 42). HLP is an early indicator of
immune suppression and is the only example of pathology
caused by permissive EBV infection (15). An unusual charac-
teristic of HLP is the frequent presence of multiple types and
strains of EBV (45, 46).
There are two distinct types of EBV, types 1 and 2, marked
by considerable sequence divergence in the coding sequences
for the EBV nuclear antigen 2 (EBNA2) and EBNA3 genes (7,
36). Type 1 was initially thought to be more prevalent than type
2; however, these studies were based on B-cell lines that were
established directly from an individual’s peripheral blood or
from naïve B cells that were infected with virus from throat
washes. Subsequent studies have revealed that type 2 is less
efficient at lymphocyte transformation and therefore would be
underrepresented in some studies of EBV prevalence in pop-
ulations (35).
Other studies of transmission have been based on restriction
enzyme polymorphisms or changes in protein size (4, 13). EBV
strains have also been distinguished by sequence changes in the
coding sequences for EBNA1, BZLF1, and LMP1 (5, 24, 29).
Multiple forms of LMP1 have been identified that are marked
by specific base pair changes, a 30-bp deletion, variable num-
bers of a 33-bp repeat region, and a 15-bp insertion within one
of the 33-bp repeats in the LMP1 coding sequence (24). These
LMP1 variants can be found in both types of EBV, although
some variants may be found preferentially in either type 1 or 2
(24, 31). It has been shown that variation in the number of
repeats may result from recombination during replication
within a single strain; therefore, the number of repeats does
not distinguish between LMP1 variants (47).
The presence or absence of the 30-bp deletion has been
widely used to distinguish EBV strains as deleted or undeleted;
however, there are also sequence variations that distinguish
strains in addition to the deletion. Seven phylogenetically dis-
tinct forms of LMP1 have been identified by their sequence
differences and signature amino acid changes (8). An eighth
strain was also described, but it was concluded to possibly be a
recombinant strain (8). The ability to precisely differentiate
between the five undeleted and three deleted strains would
enable studies of viral persistence and transmission as well as
analysis of the profile of strains during infection.
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In this study, seven of the distinct LMP1 variants identified
previously were prepared as clones in a 264-bp region within
exon 3 of LMP1 that contained representative sequence
changes for each of the variants (8). This region of LMP1 was
amplified by PCR and tested to develop a heteroduplex track-
ing assay (HTA) for LMP1. The HTA is a sensitive technique
that can distinguish sequences that have small numbers of
differences and can reveal the relative abundance of viral vari-
ants in infections with multiple strains or changing strains. In
particular, the HTA has been used to analyze the evolution of
human immunodeficiency virus (HIV) strains in patients who
develop resistance to antiviral therapy (33). The LMP1-HTA
presented here can distinguish seven LMP1 strains and also
identify subspecies of strains that were shown to have addi-
tional base pair changes from the known strain controls.
In this study, EBV strains were identified in 25 HLP biopsies
and six matched peripheral blood samples and throat wash
samples with the LMP1-HTA. The strains present and their
relative abundance in the peripheral blood, throat washes, and
HLP lesion were determined for six patients. The profile of
strains and their patterns of abundance in the blood and oral
cavity provide evidence for compartmentalization and for the
transmission of strains between the blood and oropharynx.
MATERIALS AND METHODS
Patient samples. Biopsy specimens were collected at the Infectious Disease
Clinic or Dental Clinic at the University of North Carolina Hospitals from five
HIV-positive subjects and one HIV-negative medically compromised subject
who displayed HLP. One subject also exhibited an oral lymphoma, and a biopsy
was obtained. Peripheral blood was collected by routine venipuncture, and lym-
phocytes were separated by a Ficoll step gradient. Throat wash samples were
obtained by having subjects gargle with 5 ml of sterile phosphate-buffered saline.
Tongue scrapings were collected and placed in 5 ml of sterile phosphate-buffered
saline. Two subjects gave samples at more than one visit.
Nucleic acid isolation. DNA was isolated from pulverized tissue biopsies with
a cesium chloride step gradient as previously described (32). DNA was purified
from lymphocytes with the DNeasy tissue kit (Qiagen, Valencia, Calif.). DNA
was harvested from 200 l of throat wash or tongue scraping with the High Pure
viral nucleic acid isolation kit (Roche Molecular Biochemicals, Indianapolis,
Ind.).
Amplification of LMP1. LMP1 was amplified from patient samples by nested
PCR with 200 ng of DNA template in duplicate independent reactions. The
reaction mixture contained 1 U of Taq DNA polymerase (Promega, Madison,
Wis.); a 1:10 dilution of reaction buffer; a final concentration of 2.0 mM MgCl2;
a final concentration of 10 mM of a mix containing dATP, dGTP, dCTP, and
dTTP (Promega); and 25 pmol of each primer in a 50-l reaction volume. The
first round of amplification with primers LMP-3UT (EBV genome coordinates
168017 to 168036; ATCACGAGGAATTCAATGTGGCTTTTCAGCCTAG)
(8) and FUC-HIND3 (EBV genome coordinates 168427 to 168408; ATCAGA
GAGCTTTGACAATGGCCCACATGACC) yielded a 411- or 381-bp product,
depending on the presence or absence of a 30-bp deletion.
The second round of PCR with 6 l of template from the first reaction was
performed with primers FUE-ECO (EBV genome coordinates 168163 to
168183; ATCACGAGGAATTCGTCATAGTAGCTTAGCTGAAC) (24) and
FUC-HIND3, which yielded a 264- or 234-bp product. The strain controls for the
HTA were amplified from 200 ng of cloned DNA in one round of PCR with
primers FUE-ECO and FUC-HIND3. Amplification was performed in a Robo-
cycler Gradient 96 (Stratagene, La Jolla, Calif.) for 30 to 35 cycles for each round
of PCR (1 min each of denaturation at 95°C, annealing at 55°C, and extension at
FIG. 1. EBV gene coordinates 168163 to 168427 used in this study to identify LMP1 strain variants. The locations of the primers that were used
for PCR amplification are indicated. Sequence changes relative to the prototype B958 sequence are labeled for each strain. Signature changes for
each strain are in bold. The slash marks at positions 265 to 294 denote the 30-bp deletion.
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72°C). PCR products were analyzed by 1.5% agarose gel electrophoresis and
visualized by ethidium bromide staining.
HTA. The design of the LMP1-HTA and the construction of the probes were
modeled after studies on the hypervariable V3 region of gp120 in HIV (26).
Clones were established for each of seven LMP1 variants (B958, Ch2, AL, NC,
Med, Med, and Ch1), which correspond to EBV coordinates 168163 to
168427 (8). The 264- or 234-bp fragments, depending on the presence or absence
of the 30-bp deletion, were ligated into the PGEM3Z vector (Promega). The
probes were made by digesting 5 g of plasmid with EcoRI (New England
Biolabs, Beverly, Mass.) to linearize the vector. The plasmid was end labeled for
30 min at room temperature in a reaction volume of 30 l containing 25 Ci of
[35S]dATP (Amersham Pharmacia Biotech, Arlington Heights, Ill.) and 1 U of
Klenow enzyme (New England Biolabs); following the incubation, the enzyme
was heat inactivated. The linearized vector was digested with HindIII (New
England Biolabs) to release the radiolabeled fragment from the vector. Unin-
corporated nucleotides were removed, and the probe was purified with a Quick
Spin Sephadex G-25 fine column (Boehringer Mannheim, Indianapolis, Ind.).
The heteroduplex formation reaction was performed with 8 l of PCR product
of a strain control or a patient sample, 1 l of annealing buffer (1 M NaCl, 100
mM Tris-HCl [pH 7.5], 20 mM EDTA), and 1 l of radiolabeled probe. The
mixtures were denatured for 5 min at 100°C and allowed to reanneal for 4 min
at 4°C. The reactions were separated in nondenaturing 10% polyacrylamide gels
(Hoefer apparatus; Pharmacia Biotech, San Francisco, Calif.) and subsequently
dried in a gel drier (Bio-Rad, Hercules, Calif.) and exposed to a PhosphorImager
(Molecular Dynamics, Sunnyvale, Calif.).
Sequence analysis. Sequence analysis was performed to confirm the results of
the HTA. PCR samples were sequenced directly with the primer FUE-ECO or
the undeleted specific primer LMP-FUD (EBV genome coordinates 168267 to
168287; GCCGGAATCATGACTATGAC). The samples were sequenced at the
University of North Carolina-Chapel Hill Automated DNA Sequencing Facility
on a model 377 DNA sequencer (Applied Biosystems Division, Perkin-Elmer
Cetus, Norwalk, Conn.) with the ABI Prism dye terminator cycle sequencing
ready reaction kit with AmpliTaq DNA polymerase FS (Applied Biosystems
Division, Perkin-Elmer Cetus).
RESULTS
Development of LMP1-HTA. To more finely characterize
EBV strain variation, an HTA specific for LMP1 was devel-
oped. The phylogenetically distinct LMP1 variants that have
been identified include the prototypic undeleted strain B958,
other undeleted strains (Ch2, AL, NC, and Med), and strains
with the 30-bp deletion (Med and Ch1) (Fig. 1) (8). There
are multiple strain-specific sequence changes throughout the
molecule; however, changes within the carboxyl terminus are
the most informative (8, 24). A 264-bp region in exon 3 of
LMP1 (EBV gene coordinates 168163 to 168427) that has
multiple signature changes that might enable discrimination
with an HTA for EBV genotyping was identified. Clones of this
region from each of the seven strains were produced and dif-
fered by the presence or absence of a 30-bp deletion and 7 to
14 base pair changes compared to the B958 strain, with each
strain containing at least one signature base pair change within
this region (Fig. 1). There are several common positions that
have changes in this region compared to the B958 strain, which
may indicate that the strains experienced a similar evolutionary
pressure.
HTA analysis is based on the principle that completely ho-
mologous DNA molecules, termed homoduplexes, will migrate
according to size on a polyacrylamide gel, while heterodu-
plexes will migrate more slowly because of malformations in
the DNA helix corresponding to regions of mismatch (6). The
greater the mismatch of two sequences, the slower the migra-
tion of the heteroduplex through a gel matrix. The heterodu-
plex formation reaction was performed by mixing partially ho-
mologous PCR-amplified LMP1 sequences with a radiolabeled
probe of the same region, denaturing combined DNAs and
subsequently reannealing them (Fig. 2). The resulting product
contained heteroduplexes and homoduplexes, which were then
subjected to electrophoresis through a nondenaturing gel.
Distinct migration patterns of heteroduplexes resulted, de-
pending on the strain that was used as the probe. In particular,
when a deleted or undeleted strain probe was used, the loca-
tion of the heteroduplexes in the gel was quite different. When
an undeleted probe such as Ch2 was used, the heteroduplexes
formed with undeleted strains migrated to the bottom of the
gel above the probe homoduplex, while heteroduplexes with
deleted strains were restricted in their migration due to the
30-bp mismatch bubble and were detected higher in the gel
near the single-stranded probe (Fig. 3). When a deleted probe
such as Med was used, the heteroduplexes with undeleted
strains were located high in the gel below the single-stranded
probe, while deleted strains bound to deleted probes migrated
more according to size just above the probe homoduplex.
Regardless of which strain probe was used, each lane con-
sistently contained three bands that represent probe compo-
nents (Fig. 3). The linearized vector migrated at the top of the
gel, representing the radiolabeled vector cleaved from the
LMP1 fragment. The single-stranded probe migrated in the
upper middle portion of the gel and was detected as a result of
excess probe. The probe homoduplex was formed when the
labeled strand of the probe reannealed to the complementary
unlabeled probe and migrated according to size. All strains
bound to the probe, including the homoduplex strain, migrated
slightly higher than the probe homoduplex because of short
extensions on the ends of the PCR products derived from the
primers. The intensity of the probe homoduplex and single-
stranded probe varied depending on the specific activity of the
radiolabeled probe and the relative ratio of PCR product to
probe.
In order to determine which strains would serve as the most
informative probes and produce the most discriminating pat-
FIG. 2. Schematic of the LMP1-HTA. The first step included mix-
ing of the PCR-amplified LMP1 and the radiolabeled LMP1 probe of
the same region. The mixture was denatured and allowed to reanneal.
The resulting product contained heteroduplexes and homoduplexes.
The asterisk denotes the radiolabeled strand of DNA.
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tern of heteroduplexes, probes of each of the five undeleted
strains and the two deleted strains were prepared. Each probe
was heteroduplexed to each PCR-amplified strain, and the
migration patterns were determined (Fig. 4 and 5). Comparing
the patterns of migration of heteroduplexes formed with un-
deleted strains indicated that the B958 probe did not result in
dramatic migration shifts when heteroduplexed to other unde-
leted strains (Fig. 4A). This result was not surprising because
each strain is unlike the B958 sequence to a similar extent.
When bound to the B958 probe, Med and NC had the most
restricted migration, followed by Ch2 and AL.
The Med probe also did not produce a dramatic pattern of
migrating heteroduplexes (Fig. 4B). In five of the eight posi-
tions where there were sequence changes in Med, there were
FIG. 3. Comparison of migration of heteroduplexes with undeleted and deleted probes. PCR-amplified control strains B958, Ch2, AL, NC,
Med, and Med were hybridized to (A) the undeleted Ch2 probe and (B) the deleted Med probe. Each lane contained the linearized vector,
excess single-stranded (ss) probe, and probe homoduplex. The lanes labeled probe contained only probe in the hybridization reaction.
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also changes in the other strains; therefore, the heteroduplexes
were only slightly impeded in their migration due to relatively
little mismatch. Compared to Med, NC had two additional
changes at positions 330 and 356 that increased the mismatch
in that region, so that the NC/Med heteroduplex had the
slowest migration, followed by B958, Ch2, and AL (Fig. 4B).
The remaining undeleted probes, Ch2, AL, and NC, pro-
vided more-useful heteroduplex migration profiles that more
clearly distinguished other undeleted LMP1 variants. The se-
quences of Ch2, AL, and NC are most unlike the sequences of
B958 and Med; therefore, the heteroduplexes of these
probes to B958 and Med were the most restricted in their
migration for each of these probes. When NC was used as the
probe, the migrations of the Ch2/NC and AL/NC heterodu-
plexes were quite similar (Fig. 4C). When AL was used as the
probe, the migrations of the Ch2/AL and NC/AL heterodu-
plexes were identical (Fig. 4D). When Ch2 was used as the
probe, NC was slightly more impeded than AL (Fig. 4E and
3A). The clustering of similar sequence changes within Ch2,
AL, and NC was responsible for the similar migration patterns.
When either of the deleted strains, Med and Ch1, was used
as the probe, the heteroduplexes that formed with undeleted
strains had identical patterns and migrated considerably higher
in the gel (Fig. 4F and 3B). Med and NC exhibited the most
restricted migration, followed by Ch2, AL, and B958 when a
deleted probe was used (Fig. 4F). Three possible migration
patterns resulted for deleted strains, depending on the probe
used. The migration of Med was slightly more impeded than
that of Ch1 when B958, Ch2, NC, or Med was the probe (Fig.
5A and 3A). In contrast, when Med or AL was the probe,
Ch1 migrated slightly higher than Med (Fig. 5B and 3B). The
two deleted strains were indistinguishable when Ch1 was the
probe (Fig. 5C).
Based on the migration patterns of the heteroduplexes that
were produced, combined analysis with the Ch2 and Med
probes was determined to be the most effective approach to
precisely identify the strains present in a patient sample. If an
additional base pair change is present within the defined region
of LMP1, the heteroduplex may migrate to a different position
because of the increased mismatch. For example, B958 with a
base pair change at position 266 (see subject 4, Fig. 8A) mi-
FIG. 4. Migration patterns of undeleted control strain heteroduplexes bound to each strain probe. (A) B958 probe, (B) Med probe, (C) NC
probe, (D) AL probe, (E) Ch2 probe, and (F) Med probe. The Ch1 probe yielded a pattern identical to that with the Med probe.
FIG. 5. Migration patterns of deleted strain heteroduplexes. The
strains used as the probe for each panel were (A) B958, (B) Med,
and (C) Ch1. The Ch2, NC, and Med probes produced a heterodu-
plex pattern for the deleted strains similar to that represented in panel
A. The AL probe produced a heteroduplex pattern for the deleted
strains similar to that represented in panel B.
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grated higher than the known B958 sequence when bound to
the Med probe. Ch1 strains that lack the characteristic
change at position 317 migrated similarly to Med when het-
eroduplexed to the B958 probe (data not shown). However,
when bound to the Med probe, the Ch1 substrain migrated
to the same position as the control Ch1 strain. This effect also
suggests the importance of using two strain probes to analyze
a patient sample.
Determination of detection limits of Med and Ch2 probes.
The comparisons of migration patterns for each probe indi-
cated that a probe might bind to its homoduplex strain with
more affinity than other strains, as detected by the intensity of
the homoduplex band compared to the heteroduplex bands
(Fig. 4). To evaluate the potential bias in relative abundance,
mixing experiments were performed to determine the binding
preference of a probe for its homoduplex strain versus other
strains present in the population (Fig. 6). These experiments
analyzed the binding competition that may occur between the
probe and mixed strains in a PCR sample. The Ch2 and Med
probes were mixed with increasing or decreasing concentra-
tions of strains representing 1, 10, 50, 90, and 99% of the total
population. The Ch2 and Med probes could detect Med
and Ch2, and B958 and Med, respectively, representing 1%
of the mixture (Fig. 6).
Other strain mixtures that were tested included B958 and
Med and Med and Med (data not shown). Each probe
was able to detect the presence of the strains at their lowest
concentration; however, the Med homoduplex strain was de-
tected with a greater intensity than the B958 heteroduplex
strain at the higher concentrations (Fig. 6B). These results
indicate that the HTA can depict the relative abundance of
strains in a mixed population with sufficient sensitivity to detect
strains at very low abundance. However, to eliminate any po-
tential bias that may be inherent in this assay, each patient
sample was characterized with two distinct probes to deter-
mine the relative abundance of the strains.
LMP1 strain variants in HLP patient samples. The pres-
ence of HLP is an indicator of immune system status in HIV-
positive subjects; however, HLP is not restricted to HIV-in-
fected persons (45). HLP is a keratinized hyperproliferative
lesion on the lateral borders of the tongue that is caused by
permissive EBV infection (15). In HLP, EBV replicates in the
upper differentiated epithelial layers of the tongue, but it has
not been detected in the basal layers in a latent or lytic form
(28). It is thought that HLP may develop from virus released
from mucosal lymphoid or epithelial cells (12, 46). Coinfection
of the lesion with multiple EBV types has been shown, which
permits the recombination of EBV genomes within the lesion
(46). The presence of multiple strains in HLP could be due to
infection and superinfection from endogenous and exogenous
sources.
To more thoroughly characterize EBV strain variation in
HLP, strains were identified by LMP1-HTA in the HLP lesion
of 25 patients, 6 of whom also contributed blood samples and
3 of whom contributed a throat wash sample. In addition to
HLP, one subject exhibited an EBV-positive oral lymphoma
that was also biopsied and analyzed. Multiple samples were
available from two subjects. The strains present in the samples
were determined by HTA analysis, and in some cases the PCR
products were sequenced to confirm the HTA (Fig. 7; Table 1).
These analyses indicated that a single strain was present in 3 of
25 specimens, two strains were detected in 11 of 25 specimens,
and three or more strains were detected in 11 of 25 specimens
(Table 1). The number of strains detected in a subject did not
correlate with their CD4 cell count or HIV RNA load. In
fact, five strains were detected in the HLP of the HIV-negative
medically compromised subject (subject 4), indicating that the
presence of multiple strains is not restricted to HIV-infected
subjects.
Within the HLP specimen, the relative abundance of strains
was variable, with one predominant strain in 20 of 22 samples.
In some samples, multiple deleted and undeleted strains were
present that would not have been identified in studies that
distinguished strains by the deletion alone. In addition, some
strains were detected at such low abundance that their pres-
ence could easily be missed in studies that detected strains by
cloning and sequencing.
To investigate the relationship of the virus found in the
peripheral blood to that in the HLP lesion, the strain variants
in the peripheral blood B lymphocytes and those present
within the epithelial cells in the HLP lesion (Fig. 8) and in
throat washes were identified (Fig. 8A, 8B, and 9A). In most
cases, the throat wash specimens had a strain profile similar to
that within the corresponding HLP sample, which was distinct
FIG. 6. Detection limitations for the Med and Ch2 probes were determined by mixing various strain DNAs at 1, 10, 50, 90, and 99% of the
total template, which were then subjected to PCR and HTA. (A) The Ch2 probe hybridized to decreasing amounts of Ch2 and increasing amounts
of Med. (B) The Med probe hybridized to decreasing amounts of B958 and increasing amounts of Med.
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from the strain profile detected in the peripheral blood. The
HLP sample of subject 4 contained five strains that were
present in similar amounts (B958, NC, Ch2, Med, and Ch1),
with a subset of these (NC, Med, and Ch1) detected in the
throat washes (Fig. 8A). In contrast, the pattern in the periph-
eral blood sample of subject 4 was quite distinct, with only a
single strain present that was a variant of the B958 strain with
an additional base pair change (266 A3). In this subject, the
source of strains for the HLP lesion does not appear to be the
blood.
Similarly, the HLP sample from subject 6 primarily con-
tained the Med strain, with very low levels of the B958 strain,
and the throat wash sample contained only Med (Fig. 8B).
The peripheral blood contained equal levels of B958, Ch1, and
a variant of Med that displayed a unique migration pattern.
Subject 5 also had striking compartmental differences, with a
single Ch2 strain in the blood and Med predominantly in the
HLP sample, with a trace of Ch2 (Fig. 8C). Subject 3 had a
complex pattern, with at least five strains in the HLP and five
in the blood. However, one strain in each compartment was
not detected in the other, and the relative abundance of the
strains was also distinct (Fig. 8D).
These similarities in strain patterns and abundance in HLP
and throat washes suggest that the HLP lesion may be the
source of strains in the oral cavity in these patients, although
every strain that was detected in the corresponding HLP sam-
ple was not present in the throat washes. The striking differ-
ences in some subjects between the prevalent strains in the
blood and those in the HLP and throat wash samples suggest
that the virus in the oropharynx may not be due to reactivation
of virus from peripheral blood lymphocytes and that there may
be distinct compartments of infection.
To identify possible transmission of virus between blood and
oropharynx, strains were identified in the two compartments at
two time points. In subject 1, Med, Ch1, and a very low level
of AL were detected in the throat washes, while the HLP
specimen had the same strains with the additional presence of
NC, Ch2, and trace amounts of B958 (Fig. 9A). The peripheral
blood was similar to the HLP, with detection of NC, Ch2, AL,
Ch1, and Med. The B958 strain was only detected in the HLP
at this time. At the second time point, subject 1 had an unde-
tectable HIV load and was on highly active antiretroviral ther-
apy; therefore, the subject did not have HLP. In a scraping of
the subject’s pathologically normal tongue and also in the
throat wash and peripheral blood samples, the pattern of strain
abundance was dramatically different. B958 and Med were
now the most abundant strains in all three samples, with trace
levels of NC and AL. The detection of B958, which was pre-
viously only detected in the HLP, may indicate that the B958
strain was transmitted from the oropharynx to the blood. Al-
ternatively, B958 may have been present in the blood but was
FIG. 7. Examples of LMP1-HTA patterns for HLP biopsies from
five subjects (12 to 16) analyzed with the Med probe. Only the
regions of the gel that contained heteroduplexes are shown.




1 HLP B958, AL, NC, Ch2, Med, Ch1
Blood AL, NC, Ch2, Med, Ch1
TW AL, Med, Ch1
TS (27 mo) B958, Med
Blood (27 mo) B958, Med
TW (27 mo) B958, Med
2 HLP Ch1 (317G)*
Blood Ch1 (317G)*
Lymphoma Ch1 (317G)*, B958
Blood (2 mo) Ch2
3 HLP B958*, NC, Ch2, Med, Ch1*
Blood B958, Ch2, Med, Med, Ch1
4 HLP B958, NC, Ch2, Med, Ch1
Blood B958 (266T)*
TW NC, Med, Ch1*
5 HLP Med
PBL Ch2
6 HLP B958, Med*
PBL B958*, Med, Ch1
TW B958, Med*
7 HLP B958*, Ch1 (357C)*
8 HLP Med*
9 HLP B958*, Ch1
10 HLP Med, Ch1
11 HLP B958*, Ch1 (317G)*
12 HLP B958, Ch2, Med Ch1, Med
13 HLP B958, Ch2, Ch1, Med
14 HLP B958, Ch2, Ch1, Med
15 HLP B958, Med
16 HLP B958, Med, Ch1
17 HLP B958, Ch2, Med, Ch1, Med
18 HLP B958, Med
19 HLP B958, Med, Med, Ch1
20 HLP B958, Ch1
21 HLP B958, Ch1
22 HLP B958, Med
23 HLP B958, Med, Ch1
24 HLP B958, Ch1
25 HLP B958, Med Med
a TW, throat wash; TS, tongue scraping; PBL, peripheral blood lymphocytes.
b An asterisk indicates that the strain was sequenced. The predominant strain
is shown in boldface.
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FIG. 8. (A and B) LMP1-HTA (Med probe) of EBV strain profiles from the HLP lesion (H), the peripheral blood (P), and throat wash
(T) samples of subjects 4 (A) and 6 (B). (C and D) EBV strain profiles from the HLP lesion (H) and the peripheral blood (P) samples of subjects
5 (C) and 3 (D).
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below the level of detection or was sequestered in lymphoid
tissue, possibly in the spleen or bone marrow.
In subject 2, the same strain was detected in the HLP,
peripheral blood lymphocytes, and an oral lymphoma, which
was a subspecies of Ch1 (lacking the characteristic change at
position 317) (Fig. 9B). Trace levels of B958 were also detected
in the oral lymphoma sample, which may represent infected
lymphocytes at the biopsy site, although B958 was not detected
in the peripheral blood or HLP. It is possible that the prevalent
strains in mucosal oral lymphocytes are distinct from the prev-
alent strains detected in the peripheral blood. A second blood
sample from subject 2 was obtained 2 months later, which
revealed the presence of the Ch2 strain that was not detected
in any sample at the collection 2 months prior. These analyses
reveal that EBV infection can be very dynamic, with changes in
relative strain abundance over time as well as the appearance
of new strains.
DISCUSSION
The identification of EBV strains has been used in many
studies to investigate questions concerning the biology of in-
fection and the nature of viral persistence. Many techniques
have been used to identify variants of EBV in infected people.
The establishment of lymphocyte cell lines in vitro from blood
samples or by infecting naïve B lymphocytes with virus in
throat washes has often been used to identify the EBV variants
present in a sample (4, 14, 37). DNA or protein can be har-
vested from lymphocyte cell lines and subjected to various
methods to identify differences in EBV types or strains. Se-
quence differences in the EBNA2 and -3 genes distinguish
between EBV types 1 and 2, respectively (7, 36). EBV type 2 is
less efficient at lymphocyte transformation; consequently, early
studies that analyzed the prevalence of type 1 or 2 in lympho-
cyte cell lines likely underestimated the prevalence of type 2
virus (35, 38).
A process called Ebnotyping refers to the study of EBV
nuclear antigens. The EBNAs are expressed during latent in-
fection and can vary slightly in protein size depending on the
number of repeated sequences in the gene; thus, EBV strains
have also been distinguished by the relative pattern of the size
of the EBNA proteins. Ebnotyping has been useful for studies
of transmission and persistence (13).
EBV variants that are marked by sequence polymorphisms
can be distinguished by restriction enzyme polymorphisms,
single-strand conformation polymorphism analysis, PCR, and
Southern blotting (1, 10, 18, 21, 40). However, all strains may
not be identified by these methods, which rely on specific
sequence changes or relatively large sequence differences. Sim-
ilarly, the repeat region of LMP1 has been used as a marker of
EBV strains (31, 37). Because the repeat region is subject to
intra- and interstrain recombination, the number of repeats
cannot determine the number of strains that are present, nor
can this number provide information about transmission (24).
Different strains frequently have the same number of repeats,
and the same strain can have a different number of repeat units
(47). Another method to analyze strain variants involves ob-
taining viral DNA directly from the human tissue, subjecting it
to PCR, and cloning and sequencing it (16, 47). This approach
FIG. 9. LMP1-HTA (Med probe) of EBV strain profiles from two time points for the same subjects. (A) Subject 1. HLP (H), peripheral blood
(P1), and throat wash (T1) samples from the first collection, and normal tongue scraping (TS2), peripheral blood (P2), and throat wash (T2)
samples from the second collection 27 months later. (B) Subject 2. HLP (H), peripheral blood (P1), and oral lymphoma (L) samples from the first
collection and peripheral blood (P2) sample 2 months later.
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is labor intensive and may not provide a complete representa-
tion of less-abundant strain variants.
The HTA was developed and used in this study to identify
EBV strains that have signature changes in a defined region of
LMP1 as well as provide information about the relative abun-
dance of LMP1 variants within a patient sample. Seven distinct
EBV strains have been clearly identified; an eighth strain was
reported in 2 of 92 specimens but was concluded to be either
a very rare strain or a Ch1/B958 double recombinant strain (8).
It is possible that more than the eight described strains exist.
The data presented here indicate that a given strain has a
consistent migration pattern with each individual probe. The
HTA is also sufficiently discriminatory to distinguish sub-
strains, which have a unique heteroduplex migration that rep-
resents minor base pair changes that were confirmed by se-
quence analysis. For example, a Ch1 strain that lacked the
317G3A change was detected in subjects 2 and 10 (Fig. 9B;
Table 1), and a Ch1 strain that lacked the 357C3A change was
detected in subject 7 (Table 1). Variants of B958 and Med
were also detected in subjects 4 and 6, respectively (Fig. 8A
and B). In each case, the additional base pair changes resulted
in a migration difference slightly above the position of the
parental strain.
In the study presented here, the HTA was used to analyze
strain variants in 25 subjects with the HIV-associated pathol-
ogy HLP, which has been shown to contain multiple types and
strains of EBV. The HTA was used to analyze the strain
profiles in the HLP and blood specimens from six subjects, the
HLP, blood, and throat wash specimens from three subjects,
and the HLP, blood, and oral lymphoma specimens from one
subject. These analyses revealed a complex pattern of EBV
strain variants that demonstrated the persistence of some
strains and the appearance and disappearance of other strains.
The strains in the HLP specimens had variable patterns of
abundance, with one strain typically being predominant and
several minor variants also being present. The differences in
strain abundance within the HLP itself and compared to the
peripheral blood may reflect differences in the replicative ef-
ficiency of the strains represented by LMP1 variants. It is
important to note that although differences in biological prop-
erties of LMP1 variants have been described in vitro, this study
did not identify a correlation between the presence of certain
LMP1 variants and the existence of HLP (9, 17, 23).
Intertypic recombinants between the type-specific EBNA2
and EBNA3 genes have been identified, and the LMP1 vari-
ants have been shown not to cosegregate with EBV types (48).
Therefore, the LMP1 variants may be linked to different allelic
forms of multiple EBV genes that would influence replication,
tissue tropism, or transformation. A specific viral isolate from
an individual may contain a collection of changes in many
different regions of the viral genome that may collectively
confer a growth advantage, such that it would be difficult to
link a particular strain to a disease state.
The life cycle of EBV involves two compartments, the pe-
ripheral blood and the oral cavity. The relationship of the
viruses found in these two compartments is unresolved. La-
tently infected memory B lymphocytes circulate in the periph-
eral blood and traffic through lymphoid tissues and are be-
lieved to be the site of EBV latency and persistence.
Oropharyngeal and salivary gland epithelial cells have been
shown to harbor replicative EBV; however, several studies
have suggested that the source of virus in saliva is permissively
infected tonsillar lymphocytes (2, 20, 27, 39, 41).
The data presented here revealed completely different pro-
files of EBV strains in the oropharynx and peripheral blood in
some individuals, calling into question the relationship of these
two compartments. A recent study used variation in the repeat
region of LMP1, the presence or absence of the 30-bp deletion,
and variation in the EBNA genes as markers for strain variants
to investigate the trafficking of virus between the peripheral
blood and the HLP lesion in 16 subjects (30). This study pro-
vided the initial evidence for a relationship between strains
present in the blood and HLP. In the data presented here,
several subjects had a similar strain profile in their blood and
HLP lesion, suggesting that there can be compartmental cross-
over of virus. The subsequent detection in the peripheral blood
of strains initially unique to the HLP lesion, as demonstrated in
subject 1, provides additional evidence for transmission be-
tween the oral and blood compartments.
In many of the subjects analyzed in this study, compartmen-
tal differences in the EBV strain profiles in the oral cavity and
peripheral blood were readily apparent, with one subject ex-
hibiting a dominant strain in the HLP that was not detected in
the blood. The normal tongue epithelium of an HIV-infected
person has also been shown to contain replicative EBV (44).
Furthermore, the data presented here reveal that the normal
tongue epithelium can be infected with multiple strains of
EBV. In each subject the throat wash sample contained a
subset of strains that were present in the HLP sample. As HLP
represents a lytic form of infection that is releasing virus par-
ticles into the oral cavity, it is not surprising that the strains
detected in the HLP were detected in the throat wash. How-
ever, it is interesting that if a strain was not present in the HLP
lesion, it was not detected in the throat wash.
In several examples, strains in the HLP lesion were not
detectable in the blood. This finding may indicate exogenous
infection with additional EBV strains or reflect virus reactiva-
tion and replication in salivary epithelial cells or mucosal lym-
phocytes that harbor distinct strains from peripheral lympho-
cytes. These striking differences in the relative abundance of
the EBV strains would not have been revealed with other
methods used to distinguish EBV variants. Interestingly, a
similar study of HIV compartmentalization by HTA analysis
revealed complete correlation between the strains detected
and their relative abundance in the peripheral blood and those
present in saliva (11). This finding confirmed that the blood
was the source of HIV in saliva. The differences in EBV strain
abundance between the throat wash and blood samples de-
tected here may reflect the ability of EBV to infect and repli-
cate in epithelial cells and possibly indicate that epithelial cells
are an additional distinct reservoir of persistent chronic infec-
tion.
The HTA is a powerful technique for characterizing strain
variation and may provide insight into the pathogenesis of
EBV infection. The true utility of this assay will be demon-
strated in long-term studies that will provide information about
the persistence of strains and how the strain profiles change
over time. Understanding how EBV infection changes
throughout the lifetime of the host may reveal key elements
about the development of pathology or the maintenance of the
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asymptomatic state. The complete identification of EBV
strains that infect an individual is important to elucidate the
elements of EBV infection, including virus transmission, com-
partmentalization, persistence, and the development of pathol-
ogy, all of which are poorly understood.
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